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A B S T R A C T
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development
of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has
been no change to the standard platinum and etoposide regimen for ﬁrst line treatment developed in the 1970’s.
The exceptionally high number of genomic aberrations observed in SCLC combined with the characteristic
rapid cellular proliferation results in accumulation of DNA damage and genomic instability. To ﬂourish in this
precarious genomic context, SCLC cells are reliant on functional DNA damage repair pathways and cell cycle
checkpoints.
Current cytotoxic drugs and radiotherapy treatments for SCLC have long been known to act by induction of
DNA damage and the response of cancer cells to such damage determines treatment eﬃcacy. Recent years have
witnessed improved understanding of strategies to exploit DNA damage and repair mechanisms in order to
increase treatment eﬃcacy.
This review will summarise the rationale to target DNA damage response in SCLC, the progress made in
evaluating novel DDR inhibitors and highlight various ongoing challenges for their clinical development in this
disease.
1. Introduction
The incidence of lung cancer continues to rise, with small cell lung
cancer (SCLC) currently accounting for ∼15% of cases. The highest
incidence is in Central and Eastern Europe [1] reﬂecting the direct link
between SCLC and cigarette smoking [2]. Biologically, SCLC is char-
acterised by a rapid cancer cell doubling time and early metastatic
dissemination; two thirds of patients present with metastatic (ex-
tensive) disease (ED) [3]. Drug treatment has changed little in the past
30 years and very few patients survive beyond 5 years [4]. A platinum
drug and etoposide (PE), with or without the addition of thoracic and
prophylactic cranial radiation, is the universal frontline standard of
care [4]. The aggressive nature of the disease leads to extremely rapid
deterioration and median survival of only 3–4 months without che-
motherapy [5] yet long term survival and cure can occasionally be
achieved in patients with limited stage disease (LD) [6]. In patients
with ED treatment is palliative with typical response rates of
approximately 70%, median progression free survival (PFS) and overall
survival (OS) of approximately 6 and 9 months, respectively and 1 year
survival rate of approximately 30% [7]. Unfortunately SCLC recurs in
the vast majority of patients. The only drug approved by the United
States Food and Drug Administration for treatment of relapsed SCLC in
the second line setting is topotecan [5] for which response rates are low
between 7 and 24%, progression free survival approximately 3–4
months and overall survival approximately 6–8 months [8]. Agents
such as irinotecan, temozolomide (TMZ), amrubicin and anthracycline
based regimens have also shown similar activity to topotecan in the
second line setting [9,10].
SCLC is hallmarked by rapid development of acquired chemoresis-
tance despite initial chemo and radiosensitivity (Fig. 1), with recur-
rence after initial therapy almost inevitable, usually within one year of
treatment. Around 30% of patients have primary chemoresistant or
refractory tumours and the probability of response to second-line che-
motherapy can be predicted according to response to ﬁrst-line
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treatment and the time to progression after completing it [11–14].
Patients with SCLC that relapse during ﬁrst line platinum combination
therapy or who have a treatment free interval of 60–90 days or less
after the end of ﬁrst-line therapy (resistant/refractory disease) have a
worse outcome compared to those relapsing more than 90 days after
completion of ﬁrst-line therapy (sensitive disease) [11,13,15]. Due to
the increasing tumour resistance to second line treatment and often
rapid clinical deterioration during or following second line treatment,
very few patients receive a third line of therapy. For these reasons
earlier study enrolment into trials of maintenance or ﬁrst line combi-
nation studies have become more common.
Current cytotoxic drugs and radiotherapy treatments for SCLC have
long been known to act by induction of DNA damage and the response
of cancer cells to such damage determines treatment eﬃcacy [16].
Recent years have witnessed improved understanding of strategies to
exploit DNA damage and repair (DDR) mechanisms in order to enhance
sensitivity and/or overcome resistance to conventional DNA damaging
treatments [2]. The DDR network is highly complex and dynamic with
at least 450 proteins integral to DNA repair [17]. Diﬀerent DDR pro-
teins and pathways have the ability to compensate in the absence of
integrity of the optimal pathway [16]. Five major DNA repair pathways
are known: base excision repair (BER) to repair single-strand breaks
(SSBs); homologous recombination repair (HRR) and non-homologous
end-joining (NHEJ) to repair double-strand breaks (DSBs); mismatch
repair (MMR) to repair replication errors, and nucleotide excision re-
pair (NER) to repair bulky adducts caused by platinum salts and UV
radiation, for example [16]. An armamentarium of novel DDR in-
hibitors, designed to inhibit distinct proteins critical for the integrity of
these pathways are in various stages of preclinical and clinical devel-
opment (see [16] for comprehensive review). Here we focus on the
rationale to target DDR in SCLC, the progress made in evaluating novel
DDR inhibitors and highlight various ongoing challenges for their
clinical development in this disease.
2. Rationale to evaluate DDR inhibitors in SCLC
In the setting of tobacco-related carcinogenesis the SCLC genome is
highly damaged as evidenced by an exceptionally high mutation
burden, with approximately 8.88 mutations per megabyte [3,18]. The
tumour suppressor genes TP53 and RB1 are the most commonly mu-
tated, with TP53 virtually universally mutated in SCLC. The oncogenic
transcription factors MYC and SOX2 are ampliﬁed in 27% of cases, and
histone modiﬁers such as CREBBP1 and EP300 are mutated in 15% and
13% of cases, respectively [3,19–21] (Table 1). The majority of muta-
tions have little signiﬁcance for the SCLC pathogenesis and are de-
scribed as passenger mutations. The challenge is to ﬁnd driver muta-
tions in a heterogeneous disease between patients and then being able
to use them as actionable targets for treatments. Performing whole
genome sequencing to identify therapeutically targetable oncogenic
driver mutations, George et al. detected BRAF, KIT, and PIK3CA mu-
tations in 4 out of 110 tumours analysed [3,19–21]. Although discrete,
druggable subsets akin to those observed for non-small cell lung cancer
(NSCLC) have not been identiﬁed, these results indicate that some pa-
tients might beneﬁt from genotyping and subsequent targeted therapy
[3,19–21]. The net consequence of the genomic aberrations in SCLC is
rapid cellular proliferation in the context of accumulating DNA damage
due to replication stress [22] and genomic instability. Replicative stress
is the accumulation of errors during endogenous DNA replication. DNA
repair pathways can maintain genomic integrity in times of replicative
stress but defects in regulators, checkpoints or DNA repair pathways
can result in genomic instability [23]. For instance, aberrant activation
of the oncogene MYC in an RB1 and TP53 mutant background results in
rapid proliferation and ultimately replication stress in SCLC [2]. To
ﬂourish in this precarious genomic context, SCLC cells are reliant on
functional DDR pathways and cell cycle checkpoints. However, defects
in the DDR mechanisms can be present and be compatible with tumour
survival. These aberrations create potential ‘Achilles heels’ and oppor-
tunities to selectively increase the therapeutic eﬀect of DNA-damaging
agents on cancer cells by inhibition of the remaining intact DDR.
Aberrations in DDR proteins or pathways have also been implicated in
resistance to conventional DNA damaging agents [24].
Although little is known about the molecular mechanisms in SCLC
that confer resistance to chemotherapy, three main mechanisms of
platinum resistance have been described. The ﬁrst two concern drug
handling; reduced intracellular drug accumulation and increased in-
activation of the drug, the third concerns increased capability for repair
Fig. 1. CT images of disease during treat-
ment for SCLC.
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of DNA damage [25] (Fig. 2). Platinum compounds damage DNA by
causing DNA replication barriers from the intercalation of platinum
adducts into DNA [26]. Upon uptake into cells, cisplatin is hydrolysed
in the cytoplasm and the chloride atoms are displaced by water mole-
cules [26]. Consequently, cisplatin acts as an electrophile that can react
with nitrogen on nucleic acids and sulfhydryl groups on proteins [26].
In the majority of cases, cisplatin causes 1,2-intrastrand cross-links of
purine bases and thereby hinders cell division, causing DNA damage
and leading ultimately to apoptosis [26,27]. DNA damage seems to
contribute most to cisplatin toxicity, which is underlined by the fact
that cells with deﬁcient DNA repair are hypersensitive to cisplatin [28].
The bulky adducts generated by cisplatin are repaired by nucleotide
excision repair (NER) pathway [29] and cell death depends on the
balance of DNA damage and repair [30].
In clinical studies of patients with SCLC a low expression level of
excision repair cross complementation group 1 (ERCC1), a en-
donuclease part of the NER, correlates with clinical outcome. Low
ERCC1 expression in tumours is associated with a higher response rate
and longer survival of SCLC patients with limited disease (LD) [31,32].
With respect to mechanisms of resistance to other cytotoxics, etoposide
and topotecan inhibit the topoisomerase enzymes II and I respectively,
culminating in DNA DSBs. Studies by Dingemans et al. and Karachaliou
et al. demonstrate a correlation between the survival of SCLC patients
and the expression of DNA Topoisomerase I and II [32,33]. High ex-
pression of TOPI, TOPIIA, and TOPIIB is associated with a shorter PFS in
LD patients, whereas high expression of TOPIIB is associated with low
response rates [32,33]. Although circumstantial, these ﬁndings im-
plicate a role for DDR mechanisms in chemoresistance.
Table 1
Genomic alterations in SCLC, percentages based on George et al.
Gene Alteration Pathway involved in Consequence Reference
TP53 (98%) Inactivation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3,19,21]
RB1 (91%) Inactivation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3,19,21]
RBL1 (6%) Inactivation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3]
RBL2 (6%) Inactivation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3]
TP73 (13%) Activation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3]
CDKN2A (5%) Inactivation Cell Cycle Regulation G1/S transition, proliferation, cell survival [3]
KIT (6%) Activation Receptor kinase/PI3K signalling Proliferation, cell survival, translation [3]
FGFR1 (6%) Activation Receptor kinase/PI3K signalling Proliferation, cell survival, translation [3]
PTEN (9%) Inactivation Receptor kinase/PI3K signalling Proliferation, cell survival, translation [3]
EP300 (13%) Inactivation Transcriptional Regulation Chromatin modiﬁcations [3,19,21]
CREBBP (15%) Inactivation Transcriptional Regulation Chromatin modiﬁcations [3,19,21]
MYCL1 (9%) Activation Transcriptional Regulation Cell cycle progression, cell growth [3]
MYCN (4%) Activation Transcriptional Regulation Cell cycle progression, cell growth [3]
MYC (6%) Activation Transcriptional Regulation Cell cycle progression, cell growth [3]
NOTCH familiy genes (25%) Inactivation Notch signalling/neuroendocrine diﬀerentiation Neuroendocrine markers [3]
SOX2 (27%) Ampliﬁcation Maintenance of pluripotency of stem cells SCLC proliferation [19]
Fig. 2. Cellular fate of Cisplatin.
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A further rationale to target DDR mechanisms comes from knowl-
edge that cancer cells often harbour defects and/or dysregulation of
DDR proteins and pathways [34,35]. While there is a paucity of data
speciﬁc to SCLC, Byers et al. [36] conducted an elegant study that
identiﬁed the DNA repair protein, poly (ADP-ribose) polymerase 1
(PARP 1) as a therapeutic target. A total of 34 SCLC cell lines were
proﬁled for the expression of 193 total and phosphoproteins. PARP1
was found to be highly expressed at both the mRNA and protein levels.
Preclinical SCLC models were sensitive to PARP inhibition alone and
the eﬃcacy of chemotherapy was also enhanced by the addition of a
PARP inhibitor [36]. Interestingly, SCLC cell lines revealed comparable
or higher chemosensitivity than two breast cancer cell lines with BRCA1
or PTEN mutations, and PARP inhibitor sensitivity correlated with
PARP levels [36]. Clinical studies testing several PARP inhibitors are
currently ongoing and are discussed below.
Simplistically, DDR inhibitors may have eﬃcacy in patients with
SCLC in two ways:
a) A DDR inhibitor may be synergistic when combined with a con-
ventional cytotoxic(s) through prevention of usual repair/treatment
resistance.
b) Or, a DDR inhibitor may have monotherapy activity in a genomic
context that causes vulnerability in one or more DDR pathways. This
is the concept of so-called ‘synthetic lethality’ for which the para-
digm is the well evidenced eﬃcacy of PARP inhibition in cells with
defective homologous recombination repair of DNA DSBs due to
BRCA1 or BRCA2 deﬁciency [37].
3. PARP inhibitors
The family of PARP enzymes are highly abundant nuclear proteins
that mediate BER and HRR, and alternative end joining (a-EJ). PARP1 is
crucial for the repair of SSBs and is activated by stalled replication
forks. PARP1 mediates the attachment of ADP-ribose units to multiple
proteins to restart replication forks after DNA damage repair [2]. First,
PARP1 inhibitors mediate their cytotoxic eﬀect by trapping the enzyme
to the SSB by preventing the utilization of NAD+ [38]. Second, PARP1
inhibitors inhibit PARylation and therefore binding of PARP to DNA
[38]. The resulting PARP-DNA complexes lead to collapsing and stalling
of replication forks and ultimately to the conversion of SSBs to DSBs
leading to apoptosis [38]. The development of PARP inhibitors (PARPi)
has been largely driven by the concept of synthetic lethality, in which a
combination of two deﬁciencies (in DDR) results in cell death but cells
with only one deﬁciency present remain viable. PARP inhibition is 1000
times more potent in In BRCA-deﬁcient cells in comparison to BRCA
wild-type cells [37,39]. Olaparib is the most extensively investigated
PARPi and is approved by the US FDA for use in pretreated advanced
germline BRCA mutated ovarian cancer [40]. As already indicated,
SCLC exhibits high levels of PARP1 expression and there are preclinical
data to support PARP1 inhibition for clinical evaluation as a mono-
therapy and in combination with DNA damaging agents [36,41,42]. In
tumour models PARP inhibitors synergise with agents that increase the
prevalence of SSBs such as temozolomide [43,44]. In addition, in pre-
clinical SCLC xenografts Byers et al. demonstrated single agent activity
of olaparib, which was further increased when combined with cisplatin
and etoposide or irinotecan [45]. The precise mechanism of action of
PARP inhibition in SCLC is not well understood. However, non-HRR
dependent mechanisms of PARP inhibitor sensitivity have recently been
recognised and to date candidate biomarkers for PARPi sensitivity in
SCLC identiﬁed have included a 17 DNA repair protein score [42] and
SLFN11 expression [44]. Several PARP inhibitors have now entered
clinical testing in patients with SCLC.
3.1. Olaparib
In the ﬁrst line setting single agent olaparib was tested as
maintenance treatment in a randomised, placebo-controlled phase II, 3
arm study conducted in the United Kingdom [46]. Patients were allo-
cated to one of two doses of olaparib (300 mg twice daily (bd) or
200 mg three times daily (tds)) or placebo. Eligible patients had pa-
thologically conﬁrmed LD/ED-SCLC with response to ﬁrst line che-
motherapy or chemo-radiotherapy. Patients were stratiﬁed by metas-
tasis-status and prior radiotherapy. In 220 patients randomised to
placebo, olaparib bd or oleparib tds the median PFS was 2.6 (90% CI
1.8, 3.7), 3.6 (90% CI 3.1, 6.0) and 3.6 (90%CI 3.1, 4.7) months and the
median OS was 8.9 (90% CI 7.0, 11.9), 9.9 (90% CI 7.6, 12.9) and 9.0
(90% CI 6.6, 11.8) months respectively. There was no signiﬁcant dif-
ference in PFS or OS between olaparib and placebo for either the bd or
the tds arm. There were more treatment discontinuations for olaparib
(26 in olaparib BD, 25 olaparib TDS, 17 placebo group) and the most
common toxicities were fatigue, nausea, anaemia, vomiting and anor-
exia.
In the setting of SCLC after platinum based chemotherapy (platinum
sensitive and resistant disease), an objective response rate (ORR) of
46% was observed in a phase 1/2 study of olaparib in combination with
temozolomide. An expansion to 20 patients at the recommended phase
2 dose (RP2D) is now underway [47]. In an attempt to identify pre-
dictive biomarkers, this is an innovatively designed study with inclu-
sion of baseline and serial tumour biopsies and blood samples to es-
tablish patient derived and circulating tumour derived xenograft/
explant models [48–50]. Various other trials of olaparib are ongoing
(see Table 2) including strategies to combine olaparib with other DDR
inhibitors rather than conventional cytotoxics (discussed later) and as
2nd or 3rd line monotherapy in a biomarker selected population with
relapsed SCLC harbouring somatic BRCA 1/2 mutations, ATM deﬁ-
ciency or MRE11A mutations (NCT03009682). The latter study will be
particularly interesting with respect to the frequencies of these genomic
aberrations in a trial eligible population of patients.
3.2. Veliparib
Veliparib is a potent PARP 1/2 inhibitor that was evaluated in
combination with cisplatin and etoposide in a small phase I trial in the
ﬁrst line setting if ED-SCLC. This demonstrated the ability to safely
deliver the combination of veliparib for 7 days of the 21 day cycle and
resulted in an ORR of 71% (5/7 patients, 1 complete response (CR)).
Although comparable to historical responses from chemotherapy alone
the result proved that a PARP inhibitor could be tolerated in combi-
nation with chemotherapy [51]. The subsequent ECOG-ACRIN 2511
study (NCT01642251) of veliparib added to cisplatin and etoposide
versus chemotherapy alone in the same 1st line setting was recently
reported in abstract form [52]. A total of 128 patients with ED SCLC
were randomised to receive a maximum of 4 cycles of cisplatin and
etoposide with veliparib 100 mg twice daily on days 1–7 or matching
placebo. The ORR had a mild and not statistically signiﬁcant increase
from 65.6% to 71.9% with the addition of veliparib (p = 0.57). The
median PFS was 6.1 months for patients receiving veliparib which was
statistically signiﬁcantly better than for patients receiving placebo (PFS
5.5 months, HR 0.63, p = 0.01). The median OS was 10.3 months for
patients on veliparib and 8.9 months for patients on placebo which was
not statistically signiﬁcant (HR = 0.83, p = 0.17). The veliparib and
chemotherapy combination was less well tolerated with increased
haematological toxicity, including neutropenia (9/9), leucopenia (9/9)
and anaemia (8/9). Although statistically signiﬁcant the 0.6 month
diﬀerence in median PFS had questionable meaningful clinical beneﬁt
and highlights the unmet need for predictive biomarkers to select and
enrich for patients most likely to beneﬁt. The results from a randomised
study of veliparib or placebo in combination with temozolomide as a
second or third line therapy in patients with relapsed platinum sensitive
or refractory SCLC have also been reported [53]. The ORR was sig-
niﬁcantly better for the combination (39%) compared with that for
temozolomide and placebo (14%, p value = 0.016). Disappointingly
V. Foy et al. Lung Cancer 114 (2017) 12–22
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the 4 month PFS, median PFS and OS did not diﬀer between the arms.
Also, haematological toxicity was greater for the combination (Grades 3
and 4 thrombocytopaenia 50% in the combination arm vs 9% in TMZ
arm, G3/4 neutropaenia 31% vrs 7% respectively. In this study tissue
samples from approximately half of the patients enrolled were available
for immunohistochemical (IHC) analysis of PARP1 and SLFN11 ex-
pression. There was no correlation between either biomarker with re-
sponse although a trend to high SLFN11 expression and better overall
survival was observed. SLFN11 is actively recruited to sites of DNA
damage, inhibiting HR respectively) [54] and activating a cellular re-
plication-stress response [55,56]. SLFN11 suppression has been asso-
ciated with chemoresistance in SCLC models [57] and identiﬁed as a
biomarker of PARP inhibitor response in SCLC PDX [44]. Circulating
tumour cell enumeration was undertaken at baseline and after 1 cycle
of chemotherapy. A count of< 5CTCs at baseline and after one cycle
was observed to be prognostic for better outcome, independent of
treatment received.
3.3. Talazoparib
Talazoparib is a novel and potent PARP inhibitor with a dual eﬀect
on PARP catalytic activity and PARP trapping [58]. In a phase 1 study
of 100 patients with advanced solid tumours with DNA repair pathway
defects, responses were observed in patients with BRCA mutated breast
cancer, ovarian cancer and patients with SCLC. In a subsequent ex-
pansion cohort a clinical beneﬁt rate (partial response (PR) + stable
disease (SD) > 6 weeks) of 26% (6/23) was demonstrated for talazo-
parib monotherapy among patients with platinum sensitive ED SCLC.
Talazoparib was well tolerated with 4% grade III–IV toxicities, most
commonly haematological suppression [59].
4. Mitotic inhibitors (aurora kinase and checkpoint inhibitors)
Aurora kinases play an important role in cell proliferation, con-
trolling chromatin segregation, dispensing genetic material to the new
cell during mitosis. Aurora kinase A promote mitosis through activation
of CHK1 and aurora kinase B is functionally important in cytokinesis
[60].
CHK1 prevents entry into mitosis by activating the S and G2/M
checkpoint and is involved in the co-ordination of HRR [61,62].
The tyrosine kinase Wee1 negatively regulates entry into mitosis,
arresting the cell at G2/M to enable DNA repair. Inhibition of Wee1
prevents G2/M arrest with the consequence that unchecked cells enter
mitosis resulting in cell death through mitotic catastrophe or apoptosis
[63–68].
4.1. Alisertib
Alisertib is an investigational selective aurora kinase A inhibitor,
that has demonstrated single-agent anti-tumour activity in preclinical
SCLC models and synergistic activity with paclitaxel in this setting [69].
In a phase I/II trial of Alisertib in refractory solid tumours, alisertib
demonstrated single agent activity with an ORR of 21% (n = 48) in the
relapsed SCLC subgroups of patients, considerably higher than the 4%
ORR observed in patients with NSCLC. Responses were observed in both
platinum sensitive (7/10) and platinum refractory disease (3/10) with
an overall PFS of 2.1 months [70]. However 43% of patients had serious
drug-related adverse events.
The results of a randomised phase II study of paclitaxel +/− ali-
sertib in relapsed SCLC (NCT02038647) [69] were recently presented.
Patients with relapsed SCLC < 180 days after standard ﬁrst-line pla-
tinum-based chemotherapy were randomised 1:1 to alisertib 40 mg
orally twice-daily on days 1–3, 8–10, 15–17 + paclitaxel 60 mg/m2 IV
on days 1, 8, 15 (Arm A) or matched placebo + paclitaxel 80 mg/m2
(Arm B) in 28-day cycles. Patients were stratiﬁed by type of relapse
following frontline platinum (sensitive vs resistant/refractory) and
presence/absence of brain metastases at baseline. In 178 patients ran-
domised the primary endpoint of PFS was reached with a PFS of
101 days (3.32 months) for alisertib and paclitaxel versus 66 days (2.17
months) [HR = 0.71, p = 0.038] for placebo and paclitaxel and ORRs
of 22%, and 18%, respectively. However, there was no signiﬁcant dif-
ference in OS (6.1 vs 5.4 months, p = 0.2) in the overall population.
Fig. 3. DNA damage and therapeutics.
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Interestingly a signiﬁcantly diﬀerent PFS was observed among the
subgroup of 109 patients with resistant/refractory disease where a PFS
of 2.86 months for alisertib and paclitaxel versus 1.64 months for ali-
sertib and placebo (HR = 0.66, p 0.032) was demonstrated. Further-
more, in an exploratory subgroup analysis according to expression of c-
myc by IHC in archival tumour biopsies a median PFS of 4.64 months
for alisertib and paclitaxel versus 2.27 months for placebo and pacli-
taxel (HR = 0.29, p = 0.0006) was observed. These results should be
interpreted with caution due to a sample size of only 33 patients (17
and 16 per arm). However, in the c-myc negative group (13 patients, 6
and 7 per arm), the converse was observed with an inferior PFS for
alisertib and paclitaxel of 3.32 months compared with a PFS of 5.16
months for placebo and paclitaxel (HR 11.8, p < 0.0006). Ampliﬁca-
tion and overexpression of the Myc family, a main driver oncogene
dysregulated in many cancers and involved in the regulation of Aurora
kinases transcription, occurs in 18–31% of SCLCs and may be more
common in chemo-refractory disease [71]. Preclinical studies have
demonstrated that aurora A kinase inhibitors are more eﬀective in SCLC
cell lines with myc family ampliﬁcation [71] and/or high expression of
myc [72]. A prospective study is now warranted to further evaluate the
predictive signiﬁcance of c-myc expression in the eﬃcacy of alisertib
and paclitaxel.
4.2. Prexasertib
Prexasertib is a selective ATP competitive inhibitor of CHK1 and
CHK2. In preclinical studies, prexasertib has activity as a single agent
and works synergistically with cytotoxic DNA damaging agents, indu-
cing cell death in SCLC models [73]. A phase I trial of prexasertib in
patients with advanced refractory squamous NSCLC, head and neck
cancers and anal cancers reported a partial response (PR) of 4.4% (2/
45) and SD in 33% (15/45) [74]. This agent is now being explored in
extensive stage chemosensitive and chemoresistant SCLC (NC-
T0235980).
4.3. AZD1775
AZD1775 is an oral competitive inhibitor of Wee1. As a single agent
AZD1775 is well tolerated with a favourable toxicity proﬁle and po-
tential to combine with cytotoxics or other DDR inhibitors [75]. A
phase 1 trial of AZD1775 in combination with cisplatin, carboplatin or
gemcitabine in 202 patients with refractory solid tumours demon-
strated some clinical activity with 53% (95/176) of patients obtaining
SD and 10% showing a PR. Of note, the response rates observed were
higher in patients with mutated TP53 than those possessing TP53 wild
type (21% vs 12%) [76]. This agent is now being explored in a phase II
clinical trial in patients with relapsed SCLC (NCT02593019) and in
patients with relapsed SCLC harbouring a MYC ampliﬁcation or
CDKN2A mutation, combined with TP53 mutation in a phase II trial
(NCT02688907). There is also promising preclinical data for the com-
bination of AZD1775 and the PARP inhibitor, olaparib [77], and a
phase I trial is in progress for patients with relapsed SCLC (NC-
T02511795).
5. RAD51 inhibition
RAD51 plays an essential role in homologous recombination and
DNA repair [78]. In response to DNA damage the RAD51 protein re-
locates in the nucleus and it is thought to represent sites of DNA repair
reactions [79]. RAD51 has the ability to promote joint molecule for-
mation and DNA strand exchange between homologous DNA molecules
[80–82]. In SCLC DSB repair after exposure to etoposide is RAD51
mediated [83].
5.1. Amuvatinib
Amuvatinib is a multi-targeted tyrosine kinase inhibitor, designed to
inhibitor c-KIT and PDGFRα. In preclinical studies it was found to
sensitise tumour cells to chemotherapy and radiotherapy in vitro su-
pressing RAD51 [84,85]. Amuvatinib has demonstrated synergy with
etoposide in SCLC cell lines and xenographs [86]
In preclinical studies Amuvatinib had synergistic eﬀects with DNA
damaging chemotherapies [78,84]. In a phase IB study in treatment
naive patients receiving either paclitaxel/carboplatin or carboplatin/
etoposide in combination with amuvatinib for metastatic solid tumours,
12% demonstrated a partial response (n = 12/100), of which 4 had
neuroendocrine tumours and 2 SCLC [87]. This prompted a phase 2
study in resistant relapsed SCLC with patients receiving amuvatinib in
combination with carboplatin and etoposide (ESCAPE; TrEatment of
Small Cell lung cancer with Amuvatinib in combination with Platinum
Etoposide). A clinical beneﬁt rate of 22% was reported which failed to
meet the predeﬁned study endpoint [88].
6. ATR kinase inhibition
The DDR pathway is regulated by a series of kinases including ataxia
telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR). ATM
is activated by double strand breaks and ATR recruited to single
stranded DNA coated with replication protein A, arising from DSBs or
stalled DNA replication forks. ATR in turn activates Chk1 resulting in
cell cycle arrest, promoting repair and preventing premature mitosis
[89].
Disruption of the ATM/p53 pathway is observed in up to 70% of
tumours and likely confers a growth advantage [90–92]. Disruption of
the ATM pathway drives a reliance on the ATR pathway for DDR.
Therefore inhibiting ATR in ATM deﬁcient tumours may result in syn-
thetic lethality [93].
6.1. VX-970
VX-970 is a potent and highly selective inhibitor of ATR. In a pre-
clinical study VX-970 sensitized 80% of a panel of 35 lung cancer cell
lines to cisplatin, with half of these demonstrating a greater than 10
fold increase in sensitivity. When the ATR inhibitor was compared to a
Chk1 inhibitor the drugs displayed diﬀerent sensitization proﬁles with
VX-970 the most eﬀective in combination with platinums and the Chk1
inhibitors most sensitizing to gemcitabine [94]. In the same study VX-
970 increased sensitivity to cisplatin in six out of seven NSCLC PDX
models [94]. In addition, ATR inhibitors have been shown to increase
sensitivity to topoisomerase I inhibitors in colorectal cancer cell lines in
vitro and in vivo [95], rationalising the combination of ATR inhibitors
and topotecan in early phase clinical trials in SCLC. Summary of DNA
damage pathways and therapeutics (Fig. 3).
7. Lurbinectidin
Lurbinectedin is a novel anticancer drug that inhibits activated
transcription, induces DNA double-strand breaks generating apoptosis,
and modulates tumour microenvironment. The antitumor activity and
safety of this agent in patients with SCLC has been assessed in three
clinical trials: two phase I in combination with doxorubicin or pacli-
taxel and a phase II single- agent basket trial [96]. Activity is observed
for single agent lurbinectidin (response rate 36%) and in combination
(response rates from 37 to 71%). Haematological toxicity was sig-
niﬁcant with a grade 3/4 neutropenia rate of 38% for single agent
lurbinectidin. A phase III trial in the second line setting of lurbinectidin
in combination with doxorubicin compared with standard second line
therapy (topotecan or cyclophosphamide, doxorubicin and vincristine)
is ongoing (ATLANTIS Study – NCT0256699).
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8. Perspectives
SCLC is a complex and heterogeneous tumour and the vast majority
of patients will recur with a more resistant tumour. Several targeted
agents have revolutionized the treatment of other cancers but despite
decades of clinical trials none have been approved for clinical use. DDR
inhibitors have demonstrated activity in patients with SCLC (see sum-
mary Table 3), although to date none have emerged with suﬃcient
eﬃcacy for routine clinical use. There is an unmet need to identify
biomarkers that can stratify patients into advantageous groups. In fact
an important limitation with the majority of trials has been the use of
unselected patients within a heterogeneous cancer, in other words,
targeted agents for untargeted tumours.
Currently PARP inhibitors are approved for use in BRCA mutated
ovarian cancer. BRCA mutations are rare in SCLC but scoring systems
have been proposed to predict for a ‘BRCA like’ genomic environment
[97,98]. A novel ‘DNA repair score’ consisting of 17 DNA repair pro-
teins, applied to SCLC cell lines and xenografts established that baseline
activation of the PI3K/mTOR pathway is associated with resistance to
the PARP inhibitor BMN673 [42]. Another biomarker, SLFN11 ex-
pression, is associated with PARP inhibitor sensitivity in SCLC cell lines
and PDX models [44]. In addition, high levels of SLFN11 expression (H-
score >= 1) were associated with a trend toward improved OS and
favourable tumour responses in patients with recurrent SCLC that re-
ceived TMZ and Veliparib as second line regiment, but not temozolo-
mide plus placebo in a randomised phase II clinical trial [99] high-
lighting evident biomarkers that could guide clinical decision making.
These biomarkers are dynamic and longitudinal sampling will be
required to tailor a personalised medicine approach. As a case in point,
using co-clinical models of CTC derived explant or tumour biopsy de-
rived explant tumours the expression of SLFN11 and MGMT, bio-
markers for activity of olaparib and TMZ, respectively, did not con-
sistently correlate with the tumour responses observed to these drugs in
the donor patients [47]. Correlation of identiﬁed scoring systems in
clinical studies of PARP inhibition in SCLC will be important to identity
patients most likely to beneﬁt from treatment.
In conclusion, exploration of biomarkers in vivo, from diagnostic
tumour biopsies and liquid biopsies will be crucial in identifying pa-
tients who will derive clinical beneﬁt from DDR inhibitors. While tar-
geting DDR mechanisms is theoretically plausible the results from
clinical trials to date have yet to convince. Further investigation into
the synergistic eﬀects of DDR inhibitors administered in combination
with traditional DNA damaging therapies will expand our under-
standing of how these agents are best positioned in the clinical setting
and biomarker studies may provide insight into mechanisms of ac-
quired and inherent resistance.
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